Ipsen grants Rhythm licence to non-core metabolic programmes
This article was originally published in Scrip
Executive Summary
Ipsen has granted Rhythm Pharmaceuticals an exclusive worldwide licence for the development and commercialisation of its melanocortin and ghrelin programmes.